Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This case report suggests that dutasteride may be a potential cause of cerebral venous thrombosis, as observed in a 25-year-old male presenting with headache and diplopia that improved after discontinuing the drug.

This study found that metabolic syndrome negatively affected the response to intradermal dutasteride injection in female pattern hair loss, with participants showing reduced terminal hair and increased vellus hair compared to those without the syndrome.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study found that patients on dutasteride had $20.50 lower monthly medical costs compared to those on finasteride.

BMI should be considered in future research on dutasteride's effects on fertility.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

This study found that both finasteride and dutasteride led to morphological and functional kidney damage in rats, with more severe effects observed in the dutasteride group.

In this study, oral dutasteride treatment for at least 12 months was associated with either stabilization or improvement of male-pattern hair loss in the majority of patients.

This study observed that males with androgenetic alopecia using dutasteride showed significantly improved COVID-19 outcomes, including shorter duration of symptoms and viral shedding, compared to those not using it and non-AGA males.

This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.

Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

The research concluded that in men with androgenetic alopecia, dutasteride was more effective than finasteride at increasing hair count after 24 weeks, with similar side effect profiles.

This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This study suggests that dutasteride does not present a significant risk to wild fish populations at typical environmental concentrations, but its notable bioaccumulation requires further investigation.

This study concluded that both finasteride and dutasteride therapies significantly increased chromogranin A serum levels in men with benign prostatic hyperplasia, suggesting an activation of neuroendocrine differentiation.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

In this randomized trial of Iranian men with moderate to severe androgenetic alopecia, researchers found that both finasteride and dutasteride improved hair density over 24 weeks, with dutasteride showing stronger PSA reduction but similar safety to finasteride.

This review concluded that 5α-reductase inhibitors like finasteride and dutasteride offer limited additional feminising effects in hormone therapy for transfeminine individuals, with the clearest use being androgenetic alopecia treatment; more research is needed for other potential benefits.

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.